Drug Profile
HLA-DQ2 peptide vaccine companion diagnostic - ImmusanT
Alternative Names: Nexvax2 Diagnostic - ImmusanTLatest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator ImmusanT
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coeliac disease
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Coeliac disease(Diagnosis) in Unknown
- 08 May 2017 Phase I development is ongoing in Coeliac disease (Diagnosis)
- 08 May 2017 Phase-I clinical trials in Coeliac disease (Diagnosis) (unspecified route) before May 2017 (ImmusanT company pipeline, May 2017).